{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:21:18Z","timestamp":1788355278036,"version":"build-2803163510"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Background:<\/jats:title>\n Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to improve outcomes across all heart failure (HF) phenotypes, but their role in patients undergoing transcatheter aortic valve replacement (TAVR) remains limited.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Using the TriNetX Global Collaborative Network, we identified all adults undergoing TAVR (2019\u20132025). Patients were divided into 2 groups - those receiving SGLT2i within 1-year post-TAVR and matched controls not receiving SGLT2i. Propensity-score matching was applied across demographics, comorbidities, medications, and labs. The primary endpoint was a composite of all-cause mortality and HF exacerbation. Secondary outcomes included major adverse cardiac and cerebrovascular events, ischemic stroke, acute myocardial infarction, and all-cause rehospitalization at 1 and 5 years.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Among 55,147 TAVR patients, 2,478 (4.5%) received SGLT2i. After 1:1 matching, 2,020 well-balanced patients per group were analyzed. At 1 year, SGLT2i use was associated with lower incidence of primary composite endpoint (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.69\u20130.80), HF exacerbation (HR 0.44, 95% CI 0.31\u20130.62), and all-cause rehospitalization (HR 0.41, 95% CI 0.38\u20130.44). Benefits persisted at 5 years with additional reduction in all-cause mortality (HR 0.84, 95% CI 0.73\u20130.97). Acute pancreatitis (falsification outcome) showed no association at both follow-ups.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n In a large multinational database, SGLT2i therapy after TAVR resulted in a significantly lower incidence of all-cause mortality or HF exacerbation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/hpc.0000000000000437","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:00:12Z","timestamp":1788354012000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter-2 Inhibitor Use and Outcomes Following Transcatheter Aortic Valve Replacement: A Propensity-Score Matched Analysis"],"prefix":"10.1097","author":[{"given":"Hritvik","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiran","family":"Verghese","sequence":"additional","affiliation":[{"name":"Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez M","family":"Odat","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Inglessis-Azuaje","sequence":"additional","affiliation":[{"name":"Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Kolte","sequence":"additional","affiliation":[{"name":"Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island"},{"name":"Brown University Health Cardiovascular Institute, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Dawn","family":"Abbott","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island"},{"name":"Brown University Health Cardiovascular Institute, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraschandra","family":"Vallabhajosyula","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island"},{"name":"Brown University Health Cardiovascular Institute, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HPC.0000000000000437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:00:13Z","timestamp":1788354013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/HPC.0000000000000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000437","relation":{},"ISSN":["1535-2811","1535-282X"],"issn-type":[{"value":"1535-2811","type":"electronic"},{"value":"1535-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}